Does liraglutide improve peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease?
Liraglutide improves peripheral perfusion and inflammatory/angiogenic markers in patients with type 2 diabetes and peripheral artery disease over 18 months.
In people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion, with amelioration of markers of angiogenesis and inflammation over an 18-month follow-up.
Caruso et al. (2025) studied this question.